Supriya Lifescience Limited has informed the Exchange regarding a press release dated October 01, 2025, titled "Completion of WHO GMP Audit at Ambernath facility of the Company".
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience has informed the stock exchange that it has successfully completed the WHO GMP (Good Manufacturing Practice) audit at its Ambernath manufacturing facility, as mentioned in a press release dated October 01, 2025. WHO GMP is a globally recognised quality standard required for pharmaceutical manufacturing, particularly for companies supplying regulated international markets and global health organisations. The completion of the audit means the facility meets stringent quality and compliance benchmarks set by the World Health Organization. No financial impact, capacity expansion details, or order book information was disclosed in this filing.
This is a positive compliance milestone that keeps the Ambernath facility eligible for regulated and export markets. For shareholders, it reduces regulatory risk and supports future international business, though the filing does not quantify any near-term revenue or order impact.